Voiant Expands Clinical Trial Imaging Services into Obesity and Metabolic Disease Research
Voiant is expanding its clinical trial imaging services into research for obesity and metabolic diseases. The company will offer advanced body composition and metabolic imaging endpoints to sponsors.
Voiant, a provider of clinical trial imaging services, announced on August 4, 2026, its expansion into research focused on obesity and metabolic diseases. The company plans to offer sponsors advanced body composition and metabolic imaging endpoints, moving beyond traditional weight-loss metrics.
The Waltham, Massachusetts-based firm will provide specialized imaging techniques to enhance the understanding of disease progression and treatment efficacy in metabolic conditions. This initiative is designed to supply richer data sets for clinical trials in these complex health areas.
Voiant aims to support pharmaceutical and biotechnology companies by delivering quantitative and precise imaging data. These services are intended to assist in the development of novel therapies and potentially streamline drug development timelines.
This strategic expansion reflects Voiant's objective to broaden its support across diverse therapeutic fields. The company's new focus addresses the significant global health challenge posed by obesity and metabolic disorders, aiming to contribute to the development of effective treatments.